嵌合抗原受体
FOXP3型
CD28
T细胞受体
免疫学
抗原
白细胞介素2受体
生物
T细胞
免疫系统
细胞生物学
癌症研究
作者
Russell W. Cochrane,Rob A. Robino,Bryan Granger,Eva Allen,Silvia G. Vaena,Martin J. Romeo,Aguirre A. de Cubas,Stefano Berto,Leonardo M. R. Ferreira
标识
DOI:10.1101/2024.03.31.587467
摘要
SUMMARY Regulatory T cells (Tregs) are promising cellular therapies to induce immune tolerance in organ transplantation and autoimmune disease. The success of chimeric antigen receptor (CAR) T-cell therapy for cancer has sparked interest in using CARs to generate antigen-specific Tregs. Here, we compared CAR with endogenous T cell receptor (TCR)/CD28 activation in human Tregs. Strikingly, CAR Tregs displayed increased cytotoxicity and diminished suppression of antigen-presenting cells and effector T (Teff) cells compared with TCR/CD28 activated Tregs. RNA sequencing revealed that CAR Tregs activate Teff cell gene programs. Indeed, CAR Tregs secreted high levels of inflammatory cytokines, with a subset of FOXP3 + CAR Tregs uniquely acquiring CD40L surface expression and producing IFNγ. Interestingly, decreasing CAR antigen affinity reduced Teff cell gene expression and inflammatory cytokine production by CAR Tregs. Our findings showcase the impact of engineered receptor activation on Treg biology and support tailoring CAR constructs to Tregs for maximal therapeutic efficacy. Graphical Abstract
科研通智能强力驱动
Strongly Powered by AbleSci AI